Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we identify a distinct fraction of cells in a genetically engineered mouse model of EGFR-driven GBM that respond to anti-EGFR therapy by inducing high levels of c-MET expression.
|
24115218 |
2014 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In cells and tumors that express EGFRvIII, SHP2 also antagonizes the phosphorylation of EGFRvIII and c-MET and drives expression of HIF-1α and HIF-2α, adding complexity to the evolving understanding of the regulatory functions of SHP2 in GBM.
|
24951116 |
2014 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GBM individuals with MET-pathway pairs showed significantly shorter survival times than those with only MET amplification.
|
24911613 |
2014 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exogenous expression of the ZM fusion in the U87MG glioblastoma line enhanced cell migration and invasion.
|
25135958 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review findings that associate MET expression and activity with a specific, genetically defined glioblastoma stem cell subtype, and data showing how MET sustains the stem cell phenotype in glioblastoma and other tumors.
|
23695554 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also showed that Wnt/β-catenin signaling activities in GBM are directly modulated by the addition of ligand-mediated MET activation or MET inhibition.
|
23258844 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts.
|
23359207 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the molecular factors and pathway activation signatures that determine sensitivity to c-MET inhibitors in a panel of glioblastoma and medulloblastoma cells, glioblastoma stem cells, and established cell line-derived xenografts using functional assays, reverse protein microarrays, and in vivo tumor volume measurements, but validation with animal survival analyses remains to be done.
|
23386689 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET gain was detected in primary glioblastomas (47%) and secondary glioblastomas (44%), suggesting that this genetic alteration plays a role in the pathogenesis of both glioblastoma subtypes.
|
22672415 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of MET in GBM mouse models blocks mesenchymal transition and invasion provoked by VEGF ablation, resulting in substantial survival benefit.
|
22789536 |
2012 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that expression of the MET oncogene was associated with neurospheres expressing the gene signature of mesenchymal and proneural subtypes of glioblastoma.
|
22738909 |
2012 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.
|
22020333 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
|
22162573 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition.
|
22203985 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
This phenomenon is especially common among tumors with PDGFRA amplification: overall, 43% of PDGFRA-amplified GBM were found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well.
|
22323597 |
2012 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
|
11238734 |
2001 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of HGF/SF on matrix metalloproteinase-2 (MMP-2), membrane type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitors of metalloproteinases (TIMPs), expressions of c-Met/HGF receptor-positive human glioblastoma cells.
|
10389763 |
1999 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of the c-met gene was also confirmed in a glioblastoma tissue.
|
8647632 |
1996 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We could also localize the MET amplicon to dmins in glioblastoma TX3095 by fluorescence in situ hybridization.
|
7534113 |
1995 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The oncogene MET was amplified in a glioblastoma which showed no EGFR gene amplification.
|
8017863 |
1994 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplified met gene linked to double minutes in human glioblastoma.
|
8280494 |
1993 |